Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN
Supernus Pharmaceuticals — Merger or Acquisition (May 2020)
26 slides from Supernus Pharmaceuticals's merger presentation, May 4, 2020
Slide 1: Acquisition of US WorldMeds' CNS Portfolio
Exhibit 99.2 Acquisition of US WorldMeds’ CNS Portfolio April 2020 © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus’ business strategy, goals and expec
Slide 3: Presenters
Presenters Jack Khattar President and CEO, Director Bryan Roecklein Vice President of Corporate Development Greg Patrick Sr. Vice President, CFO © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. 3
Slide 4: Overview of Transaction Details
Overview of Transaction Details Acquisition of U.S. CNS Portfolio of Total consideration of up to $530 million Upfront payment of $300 million Regulatory and commercial milestone payments of up to $230 million All cash consideration, funded through existing cash on balance sheet Transaction expected
Slide 5: Adding a Robust Neurology Portfolio with Near Term New Product Launches
Adding a Robust Neurology Portfolio with Near Term New Product Launches 2019 Net Sales: ~$150 million Operating Earnings: ~$45 million Apomorphine Pen Subcutaneous Infusion Pump Apomorphine hydrochloride subcutaneous Apomorphine hydrochloride continuous injection for acute intermittent treatment of
Slide 6: Strategic Fit & Rationale
Strategic Fit & Rationale This acquisition fits squarely with Supernus’ corporate development strategy of adding commercial and late stage neurology assets Creates Leading 1 2 Adds New CNS Portfolio Growth Catalysts Five Marketed Apomorphine Products Infusion Pump H2 2021 Strong Strategic Fit MYOBLO
Slide 7: Strategic Fit & Rationale (continued)
Strategic Fit & Rationale (continued) This acquisition fits squarely with Supernus’ corporate development strategy of adding commercial and late stage neurology assets 3 Diversifies 4 Diversifies 5 Deal Structure and Increases and Increases Aligns Revenue Base Free Cash Flow Milestones with Future U
Slide 8: Parkinson's Disease (PD) Market
Parkinson’s Disease (PD) Market US PD Market is anticipated to grow from $1.5B to $6.2B by 20261 Second most common chronic progressive neurodegenerative disorder, affecting 1-2% of individuals 65 years and older2 Number of U.S. PD Patients in 2020 is ~1M with an annual growth rate of approximately
Slide 9: Parkinson's Disease (PD) "OFF"
Parkinson’s Disease (PD) “OFF” As PD advances, patients experience more “OFF” periods ‒ Mobility & motor symptoms: Tremor, balance, slowness, dystonia, stiffness ‒ Impacts everyday life: Eating, writing, getting dressed, etc… ‒ Stigma: Fear, avoidance, and increased reliance on others Frequent and I
Slide 10: Addressing Patient Needs at Different Stages of Parkinson's Disease
Addressing Patient Needs at Different Stages of Parkinson’s Disease Stage 1 Stage 1.5 Stage 2 Stage 2.5 Stage 3 Stage 4 Stage 5 Apomorphine Pen SubQ Infusion Pump Advanced On-demand continuous Therapy treatments L-dopa Adjuncts Monotherapy Deep Brain Stimulation Generic Levodopa Initial Symptoms © 2
Slide 11: APOKYN Pen
APOKYN® Pen APOKYN Pen: Apomorphine delivered through a subcutaneous injection ‒ Well established product, with $118.9 million in sales in 2019 ‒ Best-in-class therapy for acute, rapid and reliable treatment of “OFF” Episodes in Parkinson’s Disease ‒ Successfully treats 95% of OFF episodes by 20 min
Slide 12: APOKYN Pen
APOKYN® Pen UPDRS(1) motor score change . On average, peak response seen after 20 minutes, with a meaningful clinical Time (minutes) 0 20406080100 effect seen from 4 minutes 0 . At peak effect, the mean decreases from ‐5 baseline in UPDRS motor scores were dose ‐ ‐10 24.2 points for the apomorphine
Slide 13: New Product Candidate Apomorphine Continuous Subcutaneous Infusion
New Product Candidate Apomorphine Continuous Subcutaneous Infusion Expected launch in H2 2021 ‒ Eligible for Orphan Drug Designation and 7 year exclusivity ‒ The only non-invasive continuous, dopaminergic stimulation therapy to reduce “OFF” and maximize “ON” time in PD Less invasive than currently a
Slide 14: Apomorphine Continuous Subcutaneous Infusion TOLEDO Phase III Study Results
Apomorphine Continuous Subcutaneous Infusion TOLEDO Phase III Study Results Primary outcome: Apomorphine demonstrated a 2.47 hours per day reduction in OFF time compared to placebo (0.58); p= 0.0025 Regina Katzenschlager et al, The Lancet Neurology. 2018;Vol 17(9):749-759 © 2020 Supernus Pharmaceuti
Slide 15: Apomorphine Continuous Subcutaneous Infusion TOLEDO Phase III Study Results
Apomorphine Continuous Subcutaneous Infusion TOLEDO Phase III Study Results More patients in the apomorphine group rated themselves as improved Regina Katzenschlager et al, The Lancet Neurology. 2018;Vol 17(9):749-759 © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. 15
Slide 16: Apomorphine Franchise
Apomorphine Franchise Combination product/device development requirements are challenging ‒ Patient specific human factor studies required for registration ‒ Infusion pump has the potential for Orphan Drug Exclusivity Additional support is needed to initiate and maintain patients on therapy ‒ Specia
Slide 17: MYOBLOC (rimabotulinumtoxinB Injection)
MYOBLOC® (rimabotulinumtoxinB Injection) Approved in the U.S for adults with Cervical Dystonia (CD) New indication in November 2019 for chronic sialorrhea in adults ‒ 600,000 adult patients in the U.S. suffer from chronic sialorrhea1 ‒ Up to 74% of Parkinson's patients have sialorrhea2 Global rights
Slide 18: XADAGO
XADAGO® Oral treatment of PD in adults who are having “OFF” episodes Monoamine oxidase type B (MAO-B) inhibitor that is adjunctive to levodopa/carbidopa XADAGO helps block MAO-B from breaking down dopamine in the brain Exclusive license from Zambon S.p.A in U.S territories Launched in the U.S in 201
Slide 19: A Comprehensive Commercial Platform in CNS
A Comprehensive Commercial Platform in CNS Acquired Portfolio Sales force of over 200 Sales force of ~46 representatives representatives Targeting movement disorder Sales Targeting primarily neurologists, specialists with selective coverage Force to support epilepsy and migraine of neurologists fran
Slide 20: A Robust R&D Pipeline & Platform in CNS
A Robust R&D Pipeline & Platform in CNS SPN-812 ‒ PDUFA date of November 8, Apomorphine 2020, ADHD Infusion Pump ‒ Parkinson’s disease SPN-604 ‒ Launch expected in H2 2021 Pipeline ‒ Phase III, Bipolar disorder & R&D Platform SPN-820 ‒ NV-5138 Phase I, Depression ‒ Potential expansion of SPN-817 Ind
Slide 21: Positioned For Long-Term Growth
Positioned For Long-Term Growth Diversified Neurology Portfolio Oxtellar XR® , Trokendi XR® , APOKYN®, MYOBLOC®, XADAGO® Innovative Pipeline in CNS SPN-812 Potential Launch in 2020 Apomorphine Infusion Pump Potential Launch in 2021 MYOBLOC Neurological Disorders SPN-604 SPN-817 SPN-820 (NV-5138) © 2
Slide 22: Q&A
Q&A © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. 22
Slide 23: Appendix
Appendix © 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved. 23
Slide 24: APOKYN Pen
APOKYN® Pen About APOKYN® (apomorphine hydrochloride) injection: APOKYN is used by injection, as needed, to treat loss of control of body movements in people with advanced Parkinson’s disease (PD). This condition is also called hypomobility or off episodes. An off episode may include symptoms such a
Slide 25: MYOBLOC
MYOBLOC® About MYOBLOC® (rimabotulinumtoxinB) injection: MYOBLOC is a prescription medicine that is: . injected into neck muscles and used to treat the abnormal head position and neck pain that happens with cervical dystonia in adults. . injected into the salivary glands (parotid and submandibular g
Slide 26: XADAGO
XADAGO® About XADAGO® (safinamide) tablets: XADAGO is a monoamine oxidase type B (MAO-B) inhibitor. XADAGO is used with levodopa/carbidopa to treat adults with Parkinson's disease (PD) who are having off episodes. The most common side effects seen with XADAGO are uncontrolled movements (dyskinesia),
Supernus Pharmaceuticals — Merger or Acquisition (May 2020) on 6ix